Arbor Biotechnologies secures $73.9 million to advance gene editing therapies

Arbor Biotechnologies has successfully closed a $73.9 million Series C financing led by ARCH Venture Partners and TCGX, aimed at advancing its gene editing therapeutic ABO-101 for primary hyperoxaluria type 1 (PH1). This funding is crucial as it extends Arbor's financial runway into 2027, allowing for the clinical development of its lead program and other CNS-targeted therapies. ABO-101 is designed to provide a 'one-and-done' treatment approach by reducing oxalate levels through CRISPR technology, addressing the limitations of existing monthly injections for PH1. CEO Devyn Smith expressed optimism about the potential of gene editing despite current market challenges in the biotech sector. The financing reflects investor confidence amid a cautious climate for gene therapy investments, as many companies in the space face difficulties. Arbor's advance into clinical trials is particularly significant as it marks a pivotal moment in the company's development trajectory since its inception nine years ago.